-
After sparring over Ceuta, EU states seek lessons from crisis
-
Amorim evokes spirit of Baresi as he bids revive AC Milan fortunes
-
Forest fire spreads in Dutch nature reserve
-
Suspected heatstroke kills three lions at Japan zoo
-
Japan sees 'urgent' need to boost military
-
Stocks mixed as Seoul stabilises, oil prices rise with eyes on Mideast
-
Myanmar ex-junta chief set for first Thailand visit as civilian leader
-
Trapped by war, Bangladesh seafarer recounts Gulf ordeal
-
New Zealand hooker Bell out of South Africa tour with calf strain
-
WWII shells surface in wildfire-ravaged French village
-
Trump attorney general pick looks set to clear US Senate hurdle
-
Last Scottish island bird hunt banned after almost 500 years
-
Death toll from Venezuela quakes rises past 6,000
-
Fritz outguns Jodar to win ATP Washington title
-
Shafique, Babar lead strong Pakistan reply against West Indies
-
Major League Soccer names LAFC co-owner Berg as next commissioner
-
Defending champ Shelton finding tournament sweet spot in Montreal
-
Osaka out to improve Toronto fortunes with eye on US Open
-
Democratic-led US states sue in latest challenge to Trump's tariffs
-
Dow hits fresh record as oil prices tumble
-
Trump says Iran facing 'last chance before decapitation'
-
Trump board reassures Israel after objections on Gaza pullout
-
US northwest battles wildfires after Spokane neighborhoods scorched
-
Zelensky sacks his ambassador to the US
-
Iran denies negotiating with US, drawing Trump backlash
-
'Spider-Man' breaks record for domestic box office debut
-
Key dates for the Boeing 737 MAX
-
US regulators grant long-awaited Boeing 737 MAX 7 certificate
-
Israel objects to US-backed Gaza plan, defiant on pullout
-
Eala powers past Pegula for first WTA title in Washington
-
Norway's Haugset wins stage 3 to claim Tour de France Femmes lead
-
Legionnaires' outbreak in Switzerland's Basel kills one, 26 ill
-
Cuba slowly regains power after latest nationwide blackout
-
Infantino, the FIFA president under pressure after scrapped investor plan
-
Chelsea sign England midfielder Jordan Henderson
-
Young Danes start extended military service
-
Wildfire flares up again in Greece as water bombers deployed
-
England, Wales had driest July on record: Met Office
-
Greece wildfire expert says season 'one of the worst' in a decade
-
French court rejects pro-Kremlin commentator's deportation appeal
-
Sandoz strikes US settlements to resolve generic drug price dispute
-
Oil slides, stocks rise on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan, keeps up strikes on territory
-
EU chief urges 'united action' on borders after Ceuta migrant rush
-
Inside Capital Regency's Market Expansion and User Acquisition
-
Oil prices slide on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan and keeps striking
-
Dortmund sign Greek teenager Karetsas from Genk
-
Bangladesh measles outbreak drives families into debt: aid groups
-
Detained Aung San Suu Kyi meets Red Cross delegate in Myanmar
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection
Delivering Effective Germ Control in Five Minutes
BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.*
NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential.
"We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patient safety and manage infections more effectively."
The European Centre for Disease Prevention and Control reports that these infections result in over 3.5 million cases each year in the EU and EEA, causing more than 90,000 deaths. Effective infection control practices could prevent up to 50% of healthcare-associated infections (HAIs).* NUGEN® HLD-CD delivers powerful protection - arming frontline healthcare teams with a fast, effective tool to stop infections before they spread.
Additionally, NUGEN® HLD-CD is an ideal solution for targeting Clostridium difficile (C. diff) contamination*, a common and challenging pathogen in healthcare settings that spreads via contact with contaminated surfaces.
For more information about NUGEN® HLD-CD and its applications, please visit https://www.arxada.com/en/hygiene/hygiene-emea/nugen-hld-cd or contact [email protected]
Media contacts:
Tricia Ryan
External Corporate Communications
Arxada
[email protected]
Jane Smith
Marketing Communications, Professional Hygiene
Arxada
[email protected]
About Arxada
Arxada is a global science-based specialty chemicals business creating innovative chemistry and solutions. With customers in more than 100 countries, it achieved sales of CHF 2.0 billion in 2023. The company aims to solve the world's toughest preservation challenges by enhancing sustainability with cleaner, greener solutions. Arxada focuses on multiple end-markets, primarily in: Human Health & Nutrition, Home & Personal Care, Paints & Coatings and Wood Protection, providing a broad portfolio of differentiated products and solutions, supported by its and innovation capabilities, in-depth regulatory know-how and track record in manufacturing and process development. Headquartered in Basel (Switzerland), the company's 3,400 employees contribute to the success of its customers, spanning 24 production sites and 14 R&D centers. To learn more about Arxada, please visit: www.arxada.com and Arxada on LinkedIn.
This product is intended for use as a medical device within the European Union and is sold exclusively to healthcare professionals. It has undergone a conformity assessment to ensure compliance with EU regulations, including the Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. The product is designed to meet the highest standards of safety and performance. Users are advised to follow the instructions for use provided by the manufacturer. The manufacturer is not liable for any misuse or off-label use of the product. All trademarks belong to Arxada or its affiliates. © 2025 Arxada.
*Data on file with Arxada; based on internal and external testing
SOURCE: Enviro Tech Chemical Services, Inc.
View the original press release on ACCESS Newswire
O.Lorenz--BTB